Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




DNA Analysis Systems Reduce DNA Input and Increase Sample Throughput

By Labmedica staff writers
Posted on 16 Jan 2008
Two new products for DNA analysis double sample throughput and reduce DNA input requirements by as much as 70%. More...
They offer enhanced signal discrimination and a new single nucleotide polymorphism (SNP) algorithm.

Launched by Illumina's (San Diego, CA, USA) microarray business, the two new products are on the Human1M-Duo beadchip and contain markers for more than one million diverse genetic variants, all of which can be used for both whole-genome genotyping and copy number variation (CNV) analysis.

In addition to Human1M single-sample BeadChip, Illumina's new Human1M-Duo features can identify disease-associated SNPs and intelligently select high-density SNPs in coding regions of the genome. The Human1M-Duo also provides the highest available power to detect SNPs associated with diseases and the least number of large gaps for the identification of CNVs.
The Infinium HD Human1M-Duo (two samples/chip) and the Human610-Quad (four samples/chip), feature up to 2.3 million single nucleotide polymorphisms (SNPs) per beadchip. First customer shipments of the Human610-Quad and Human1M-Duo beadchips are expected in the first and second quarters of 2008, respectively.

The four-sample format of the Human610-Quad beadchip provides customers with a significant increase in sample throughput and reduced handling in the lab. Built upon the content of Illumina's broadly adopted HumanHap550 beadchip, the Human610-Quad beadchip has 550,000 SNPs plus an additional 60,000 genetic markers per sample. Both the Infinium HD Human1M-Duo and Human610-Quad beadchips include high-value, CNV content developed in conjunction with deCODE genetics, only found on Illumina arrays.

"The Human1M-Duo and Human610-Quad beadchips provide our customers with significant advances, including increased sample throughput, lower input sample volume, and improvements to the Infinium assay that enhance overall system performance. Concurrent with the development of these new array products, Illumina has implemented new decoding instruments into its operations that will effectively double Illumina's array manufacturing capacity over the next several quarters,” said John Stuelpnagel, senior vice president, COO, and general manager of Illumina's Microarray Business.

Illumina's genotyping solutions offer a flexible beadchip design and high-density architecture. Infinium HD products provide a powerful complement to Illumina's genotyping offering, which includes Infinium II, iSelect Infinium, GoldenGate, and VeraCode genotyping products.


Related Links:
Illumina

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.